Bioheart
Bioheart is a small, delisted biotech company founded in 1999 in Sunrise, Florida, developing cell-based technologies to treat cardiovascular diseases. It operates with 11-50 employees and has not raised capital since 2014.
- Company typePrivate
- Founded1999
- HeadquartersSunrise, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioheart does
Bioheart is a privately operating biotech company founded in 1999 and headquartered in Sunrise, Florida. The company focuses on developing cell technologies intended to treat cardiovascular diseases, positioning itself within the regenerative medicine and cardiac cell therapy segment of the biotech industry. Historically a publicly listed entity on NASDAQ under the ticker BHRT, Bioheart is currently delisted and operates with a small employee base of 11-50 people. The company is led by founder and Chairman William P. Murphy, with Mike Tomas serving as President & CEO and Charles Hart as Director, reflecting a lean executive bench consistent with a clinical-stage or pre-commercial organization.
The company's core business centers on the research, development, and clinical translation of cell-based therapies for cardiovascular indications. Specific platform architecture, candidate pipeline composition, regulatory milestones (e.g., IND filings, FDA designations), manufacturing processes, and proprietary scientific differentiators are not described in the available source material. No commercial products, licensing arrangements, royalty streams, or third-party endorsements of the underlying technology are documented. As a result, the precise therapeutic targets, modality (autologous vs. allogeneic, stem cell vs. progenitor, etc.), and clinical development stage cannot be determined from the input.
From a capitalization standpoint, Bioheart has raised approximately $19.95 million across eight disclosed funding events between 2001 and 2014. The most notable rounds were a $15.0 million financing in 2005 from Advent-Morro Equity Partners, BioMedPartners, and Magellan Bioscience Group, and a $3.0 million round in 2014 from Magna. Earlier non-dilutive or partnership-linked transactions included a 2001 arrangement with Guidant and a 2008 financing from Rogers Communications. The absence of capital raises since October 2014, combined with delisted status and undisclosed revenue, indicates the company has operated without meaningful external financing for over a decade, raising questions about current operating tempo, pipeline progression, and runway. There is no evidence of active partnerships, awards, certifications, geographic expansion, AI/ML capability development, or customer relationships in the source material.
Bioheart firmographics
Firmographics- Name
- Bioheart
- Website
- https://bioheartinc.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bioheart is a small, delisted biotech company founded in 1999 in Sunrise, Florida, developing cell-based technologies to treat cardiovascular diseases. It operates with 11-50 employees and has not raised capital since 2014.
- Ownership category
- akta.pro rank
Bioheart industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)
Keywords
Where Bioheart is headquartered
LocationHeadquarters
- HQ city
- Sunrise
- HQ country
- United States
- HQ region
- North America
Markets served
Bioheart business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Bioheart product offering
Product offeringCore offering
Bioheart is a biotechnology company focused on the research, development, and commercialization of cell-based technologies intended to treat cardiovascular diseases. The company develops biological cell therapies designed to regenerate and repair damaged heart tissue, targeting conditions such as heart failure and ischemic cardiovascular disease through autologous and regenerative cell platforms.
Differentiator
Problem solved
Functional benefit
Products and services
- Cardiovascular Cell Therapy Platform Proprietary cell-based technology developed to treat cardiovascular diseases by regenerating damaged heart tissue, intended for healthcare providers and clinical investigators in cardiology.
Companies that use Bioheart
Customer profileIdeal customer profiles1 record
Bioheart technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bioheart partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Bioheart competitors and assessment
Company assessmentDirect peers
- Mesoblast: Commercial-stage regenerative medicine company with cardiac cell therapy programs (revascor for chronic heart failure) — comparable in both modality (cell therapy) and target indication (cardiovascular disease).
- Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic cell products with programs in critical limb ischemia and cardiovascular indications — comparable regenerative cell therapy platform.
- BioCardia: Cardiology-focused cell therapy company developing autologous and allogeneic cell therapies delivered via proprietary catheter systems for heart failure — directly comparable in cardiac cell therapy modality.
- Capricor Therapeutics: Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy-associated cardiomyopathy and other cardiac indications — directly comparable cardiac cell therapy focus.
- BrainStorm Cell Therapeutics: Cell therapy company developing autologous neurotrophic factor-secreting cell therapies — comparable small-cap clinical-stage cell therapy peer with similar funding and operational profile.
- Vericel: Cell therapy company commercializing autologous cell-based products (MACI, Epicel) — comparable in the autologous cell therapy modality applied to medical indications, including burn and cartilage repair.
- Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy platform with programs in cardiovascular, neurological, and inflammatory indications — comparable cell therapy peer with cardiovascular program history.
- Cytori Therapeutics: Developer of cell therapy technologies (Celution system) originally applied to cardiovascular disease — directly comparable historical peer in cardiac cell therapy with autologous cell processing platform.
- Caladrius Biosciences: Clinical-stage cell therapy company with CD34+ cell programs in ischemic conditions including cardiovascular disease — comparable small-cap cardiac cell therapy peer.
Emerging players
- BlueRock Therapeutics: Engineered cell therapy company (now Bayer-owned) developing iPSC-derived cell therapies, including cardiac programs for heart failure — emerging player in next-generation cardiac cell therapy that competes for the same therapeutic opportunity.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Bioheart social profiles
Digital presenceBioheart financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioheart leadership team
Management profileNumber of profiles
Profiles3 records
Bioheart funding detail
Funding detailFunding overview
Funding rounds8 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioheart M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioheart
What does Bioheart do?
Bioheart is a biotechnology company focused on the research, development, and commercialization of cell-based technologies intended to treat cardiovascular diseases. The company develops biological cell therapies designed to regenerate and repair damaged heart tissue, targeting conditions such as heart failure and ischemic cardiovascular disease through autologous and regenerative cell platforms.
Is Bioheart a public or private company?
Bioheart is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bioheart founded?
Bioheart was founded in 1999. It employs 11 to 50 people.
Where is Bioheart based?
Bioheart is headquartered in Sunrise, United States, in the North America region.
Who are Bioheart's main competitors?
Direct peers on record are Mesoblast, Pluristem Therapeutics, BioCardia, Capricor Therapeutics, BrainStorm Cell Therapeutics, Vericel, Athersys, Cytori Therapeutics and Caladrius Biosciences. BlueRock Therapeutics is listed as an emerging player.
Does Bioheart have an API?
No public API is recorded for Bioheart.
What industry is Bioheart in?
Bioheart's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 2836.